Related Experiment Video
Updated: Jun 2, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
Published on: July 28, 2023
Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials
Humphrey Mulenga1, Sizulu Moyo, Lesley Workman
1South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa.
Insights
Defining infant tuberculosis (TB) vaccine trial endpoints requires matching the TB disease phenotype. This study analyzed clinical, radiological, and microbiological features to estimate case frequency for TB vaccine trials.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Infant tuberculosis (TB) vaccine trials require precise endpoint definitions.
- The expected TB disease phenotype in control groups influences endpoint selection.
- Accurate estimation of TB case frequency is crucial for trial design.
Purpose of the Study:
- To analyze combinations of clinical, radiological, and microbiological features of pulmonary TB in children.
- To estimate case frequency for various TB phenotypes under vaccine trial conditions.
- To inform the definition of endpoints for infant TB vaccine trials.
Main Methods:
- Retrospective analysis of 2,185 South African children investigated between 2001-2009.
- Evaluation of TB exposure, symptoms, chest radiography (CXR), and Mycobacterium tuberculosis culture.
- Assessment of discordance between diagnostic features and case definitions.
Main Results:
- TB exposure and symptoms were more common than CXR or culture-positive TB.
- Significant discordance observed between clinical, radiological, and microbiological findings.
- Annual incidence of culture-positive TB declined to <0.2%, while a triad of exposure, symptoms, and CXR reached ~1% in children <2 years.
Conclusions:
- Endpoint definitions for infant TB vaccine trials must align with the expected TB disease phenotype.
- Benchmarking diagnostic data against key indicator variables is essential for modeling TB case frequency.
- Findings support the development of robust endpoints for infant TB vaccine trials.
Abstract:
The endpoint definition for infant tuberculosis (TB) vaccine trials should match the TB disease phenotype expected in the control arm of the study population. Our aim was to analyse selected combinations of the clinical, radiological, and microbiological features of pulmonary TB among children investigated under vaccine trial conditions, in order to estimate case frequency for a range of expected TB phenotypes. Two thousand one hundred and eighty five South African children were investigated over a nine-year period (2001-2009). Evidence of TB exposure and classical symptoms were several times more common than chest radiography (CXR) compatible with TB, or positive Mycobacterium tuberculosis culture. Discordance between clinical, radiological, and microbiological features was common in individual children. Up to one third of children with compatible CXR, and up to half the children who were M. tuberculosis culture positive, were asymptomatic. The culture positive rate fell over time, although rates of TB exposure and compatible chest radiography increased. Consequently, the annual incidence of diagnostic combinations that included M. tuberculosis culture fell to <0.2%. However, in this study population (children <2 years of age), annual incidence of the TB disease phenotype that included the triad of TB exposure, symptoms, and compatible CXR, approached 1% (n=848 per 100,000). These findings allow modelling of expected TB case frequency in multi-centre infant TB vaccine trials, based upon benchmarking of diagnostic data against the key indicator variables that constitute the building blocks of a trial endpoint.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis
